Hypomethylation-Enhanced F-Box Protein 32 Promotes Hepatocellular Carcinogenesis via Ubiquitin-Mediated PHLPP2 Degradation

Abstract

F-Box Protein 32 (FBXO32), a F-box protein family member, exhibits oncogenic and tumor-suppressive roles in various carcinomas. However, its function and underlying molecular mechanisms in hepatocellular carcinoma (HCC) are still unknown. We observed that FBXO32 was overexpressed in HCC tissues than normal tissues, which is pertaining to poor prognosis in HCC patients. Functional tests demonstrated that FBXO32 enhanced HCC cell proliferation, invasion, and metastasis, which was confirmed in vivo using mouse models. Proteomics-based approaches and computational analyses reported a positive correlation between FBXO32 and PI3K–AKT pathway, identifying pleckstrin homology domain leucine-rich repeat protein phosphatase 2 (PHLPP2) as an interacting protein. Mechanistically, DNA promoter hypomethylation elevated FBXO32 expression in HCC cells, promoting K48-linked PHLPP2 polyubiquitination at the K592 and K942 sites through direct interactions. Notably, targeting FBXO32 significantly inhibited tumor growth in both an orthotopic HCC model and an organoid model derived from HCC patients. To sum up, this work emphasizes the part of FBXO32 in propelling HCC progression via facilitating PI3K–AKT pathway activation via PHLPP2 degradation.

Keywords

biomarker / DNA methylation / E3 ubiquitin ligase / PI3K–AKT pathway

References

[1] F. Foerster, S. J. Gairing, S. I. Ilyas, and P. R. Galle, “Emerging Immunotherapy for HCC: A Guide for Hepatologists,” Hepatology (Baltimore, Md) 75, no. 6 (2022): 1604-1626.

[2] H. Liu, L. Xu, S. Yue, et al., “Targeting N4-Acetylcytidine Suppresses Hepatocellular Carcinoma Progression by Repressing eEF2-Mediated HMGB2 mRNA Translation,” Cancer Communication (London) 44 (2024): 1018-1041.

[3] G. Cabibbo, C. Celsa, L. Rimassa, et al., “Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices,” Journal of Hepatology 80 (2024): 957-966.

[4] Q. Gao, N. Li, Y. Pan, et al., “Hepatocyte Growth Factor Promotes Melanoma Metastasis through Ubiquitin-Specific Peptidase 22-Mediated Integrins Upregulation,” Cancer Letters 604 (2024): 217196.

[5] Y. Lu, Y. Sun, J. Zhang, et al., “The Deubiquitinase USP2a Promotes Tumor Immunosuppression by Stabilizing Immune Checkpoint B7-H4 in Lung Adenocarcinoma Harboring EGFR-Activating Mutants,” Cancer Letters 596 (2024): 217020.

[6] Y. Bian, S. Xu, Z. Gao, et al., “m6A Modification of lncRNA ABHD11-AS1 Promotes Colorectal Cancer Progression and Inhibits Ferroptosis Through TRIM21/IGF2BP2/FOXM1 Positive Feedback Loop,” Cancer Letters 596 (2024): 217004.

[7] J. Liu, M. Zhai, Y. Chen, et al., “Acetylation-Dependent Deubiquitinase USP26 Stabilizes BAG3 to Promote Breast Cancer Progression,” Cancer Letters 597 (2024): 217005.

[8] L. Zhao, N. Yu, Y. Zhai, et al., “The Ubiquitin-Like Protein UBTD1 Promotes Colorectal Cancer Progression by Stabilizing c-Myc to Upregulate Glycolysis,” Cell Death & Disease 15, no. 7 (2024): 502.

[9] Y. Liao, W. Zhang, Y. Liu, C. Zhu, and Z. Zou, “The Role of Ubiquitination in Health and Disease,” MedComm 5, no. 10 (2024): e736.

[10] C. Ding, L. Cao, R. Wang, et al., “OTUD7B Is a New Deubiquitinase Targeting p53,” Theranostics 15, no. 6 (2025): 2121-2138.

[11] S. Chen, L. Zhao, J. Liu, et al., “Inhibition of KIF20A Enhances the Immunotherapeutic Effect of Hepatocellular Carcinoma by Enhancing c-Myc Ubiquitination,” Cancer Letters 598 (2024): 217105.

[12] J. Zhu, L. Wang, X. Nie, et al., “RBMS3-Loss Impedes TRIM21-Induced Ubiquitination of ANGPT2 in an RNA-Independent Manner and Drives Sorafenib Resistance in Hepatocellular Carcinoma,” Oncogene 44 (2025): 1620-1633.

[13] H. B. Park and K. H. Baek, “Current and Future Directions of USP7 Interactome in Cancer Study,” Biochimica et Biophysica Acta Reviews on Cancer 1878, no. 6 (2023): 188992.

[14] Y. Deng, W. Ding, K. Ma, et al., “SPOP Point Mutations Regulate Substrate Preference and Affect Its Function,” Cell Death & Disease 15, no. 2 (2024): 172.

[15] G. P. Grothusen, R. Chang, Z. Cao, et al., “DCAF15 Control of Cohesin Dynamics Sustains Acute Myeloid Leukemia,” Nature Communications 15, no. 1 (2024): 5604.

[16] W. Chang, Q. Luo, X. Wu, et al., “OTUB2 Exerts Tumor-Suppressive Roles via STAT1-Mediated CALML3 Activation and Increased Phosphatidylserine Synthesis,” Cell Reports 41, no. 4 (2022): 111561.

[17] G. Saha, S. Roy, M. Basu, and M. K. Ghosh, “USP7 - A Crucial Regulator of Cancer Hallmarks,” Biochimica et Biophysica Acta Reviews on Cancer 1878, no. 3 (2023): 188903.

[18] Y. Qi, A. H. Rezaeian, J. Wang, et al., “Molecular Insights and Clinical Implications for the Tumor Suppressor Role of SCF(FBXW7) E3 ubiquitin ligase,” Biochimica et Biophysica Acta Reviews on Cancer 1879, no. 5 (2024): 189140.

[19] J. Z. Shen, Z. Qiu, Q. Wu, et al., “FBXO44 Promotes DNA Replication-Coupled Repetitive Element Silencing in Cancer Cells,” Cell 184, no. 2 (2021): 352-369.e23.

[20] Z. Chen, D. Ren, J. Lv, et al., “The Atypical Ubiquitin Ligase RNF31 Stabilizes c-Myc via Epigenetic Inactivation of FBXO32 and Promotes Cancer Development,” Cellular Signalling 107 (2023): 110677.

[21] N. Zhang, Y. Liao, W. Lv, et al., “FBXO32 Targets PHPT1 for Ubiquitination to Regulate the Growth of EGFR Mutant Lung Cancer,” Cellular Oncology (Dordrecht, Netherlands) 45, no. 2 (2022): 293-307.

[22] D. Su, R. Wang, G. Chen, et al., “FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis,” Cancer Research 84, (2024): 2607-2625.

[23] S. K. Sahu, N. Tiwari, A. Pataskar, et al., “FBXO32 Promotes Microenvironment Underlying Epithelial-Mesenchymal Transition via CtBP1 During Tumour Metastasis and Brain Development,” Nature Communications 8, no. 1 (2017): 1523.

[24] J. Wu, T. Wen, A. Marzio, et al., “FBXO32-Mediated Degradation of PTEN Promotes Lung Adenocarcinoma Progression,” Cell Death & Disease 15, no. 4 (2024): 282.

[25] M. D. Wang, X. J. Xu, K. C. Wang, et al., “Conversion Therapy for Advanced Hepatocellular Carcinoma in the Era of Precision Medicine: Current Status, Challenges and Opportunities,” Cancer Science 115, no. 7 (2024): 2159-2169.

[26] J. M. Llovet, R. Pinyol, M. Yarchoan, et al., “Adjuvant and Neoadjuvant Immunotherapies in Hepatocellular Carcinoma,” Nature Reviews Clinical Oncology 21, no. 4 (2024): 294-311.

[27] J. Chen, N. A. Kaya, Y. Zhang, et al., “A Multimodal Atlas of Hepatocellular Carcinoma Reveals Convergent Evolutionary Paths and ‘Bad Apple’ Effect on Clinical Trajectory,” Journal of Hepatology 81 (2024): 667-678.

[28] Z. D. Smith, S. Hetzel, and A. Meissner, “DNA Methylation in Mammalian Development and Disease,” Nature Reviews Genetics 26, no. 1 (2025): 7-30.

[29] L. D. Moore, T. Le, and G. Fan, “DNA Methylation and Its Basic Function,” Neuropsychopharmacology 38, no. 1 (2013): 23-38.

[30] A. Van Tongelen, A. Loriot, and C. De Smet, “Oncogenic Roles of DNA Hypomethylation Through the Activation of Cancer-Germline Genes,” Cancer Letters 396 (2017): 130-137.

[31] R. Zhang, J. Dai, F. Yao, et al., “Hypomethylation-Enhanced CRTC2 Expression Drives Malignant Phenotypes and Primary Resistance to Immunotherapy in Hepatocellular Carcinoma,” iScience 27, no. 6 (2024): 109821.

[32] X. T. Lin, Y. D. Luo, C. Mao, et al., “Integrated Ubiquitomics Characterization of Hepatocellular Carcinomas,” Hepatology (Baltimore, Md) 82, no. 12025: 42-58.

[33] Q. Gong, L. Zhang, J. Guo, et al., “FBXO Family Genes Promotes Hepatocellular Carcinoma via Ubiquitination of p53,” Journal of Cancer Research and Clinical Oncology 150, no. 10 (2024): 458.

[34] E. Y. Cai, M. N. Kufeld, S. Schuster, et al., “Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress,” Cell Stem Cell 27, no. 2 (2020): 270-283.e7.

[35] J. Xu, P. Shi, F. Xia, et al., “RAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway,” International Journal of Molecular Sciences 23, no. 19 (2022): 12036.

[36] R. Li, X. Yan, W. Zhong, et al., “Stratifin Promotes the Malignant Progression of HCC via Binding and Hyperactivating AKT Signaling,” Cancer Letters 592 (2024): 216761.

[37] Z. Xue, J. Liu, W. Xing, et al., “Hypoxic Glioma-Derived Exosomal miR-25-3p Promotes Macrophage M2 Polarization by Activating the PI3K-AKT-mTOR Signaling Pathway,” Journal of Nanobiotechnology 22, no. 1 (2024): 628.

[38] L. Peng, J. Fu, Y. Chen, et al., “Transcription Factor SNAI2 Exerts Pro-Tumorigenic Effects on Glioma Stem Cells via PHLPP2-Mediated Akt Pathway,” Cell Death & Disease 13, no. 6 (2022): 516.

[39] N. Liu, X. Jiang, L. Guo, et al., “Mutant p53 Achieved Gain-of-Function by Promoting Tumor Growth and Immune Escape Through PHLPP2/AKT/PD-L1 Pathway,” International Journal of Biological Sciences 18, no. 6 (2022): 2419-2438.

[40] D. Kang, H. J. Hwang, Y. Baek, et al., “TRIM22 Induces Cellular Senescence by Targeting PHLPP2 in Hepatocellular Carcinoma,” Cell Death & Disease 15, no. 1 (2024): 26.

[41] J. Tantai, X. Pan, Y. Chen, Y. Shen, and C. Ji, “TRIM46 Activates AKT/HK2 Signaling by Modifying PHLPP2 Ubiquitylation to Promote Glycolysis and Chemoresistance of Lung Cancer Cells,” Cell Death & Disease 13, no. 3 (2022): 285.

[42] X. Li, P. D. Stevens, H. Yang, et al., “The Deubiquitination Enzyme USP46 Functions as a Tumor Suppressor by Controlling PHLPP-Dependent Attenuation of Akt Signaling in Colon Cancer,” Oncogene 32, no. 4 (2013): 471-478.

[43] K. Kim, D. Ryu, P. Dongiovanni, et al., “Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis,” Gastroenterology 153, no. 6 (2017): 1568-1580.e10.

[44] J. Zhu, J. Tang, Y. Wu, X. Qiu, X. Jin, and R. Zhang, “RNF149 Confers Cisplatin Resistance in Esophageal Squamous Cell Carcinoma via Destabilization of PHLPP2 and Activating PI3K/AKT Signalling,” Medical Oncology (Northwood, London, England) 40, no. 10 (2023): 290.

[45] L. Liu, B. Guo, Y. Han, S. Xu, and S. Liu, “MARCH1 Silencing Suppresses Growth of Oral Squamous Cell Carcinoma Through Regulation of PHLPP2,” Clinical & Translational Oncology 24, no. 7 (2022): 1311-1321.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.